Profile data is unavailable for this security.
About the company
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States. Its digital solutions consist of three primary solution categories: Marketing, Reputation and Experience. Its Marketing solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators, and enhanced segmentation tools to evaluate the needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. The Company's Experience solutions are provided on a subscription basis via a cross-continuum multi-mode digital platform. Its Reputation solutions allow healthcare organizations to share a picture of their organization.
- Revenue in USD (TTM)147.42m
- Net income in USD30.36m
- Incorporated1997
- Employees435.00
- LocationNational Research Corp1245 Q StLINCOLN 68508United StatesUSA
- Phone+1 (402) 475-2525
- Fax+1 (402) 475-9061
- Websitehttps://nrchealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 632.48m | 57.00 | -- | 3.19 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 634.01m | 28.00 | -- | 1.93 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 634.09m | 73.00 | -- | 5.28 | -- | 48.83 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 634.24m | 53.00 | -- | 1.70 | -- | 196.73 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Harrow Inc | 138.68m | -31.33m | 635.11m | 315.00 | -- | 10.49 | -- | 4.58 | -0.9079 | -0.9079 | 4.09 | 1.71 | 0.5406 | 4.21 | 6.75 | 440,244.40 | -12.21 | -10.86 | -13.79 | -12.71 | 69.77 | 70.75 | -22.59 | -15.35 | 2.75 | -0.3302 | 0.7536 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Sinovac Biotech Ltd | 448.27m | -105.90m | 639.90m | 3.04k | -- | -- | -- | 1.43 | -1.08 | -1.08 | 4.19 | 87.41 | 0.0323 | 1.13 | 0.9175 | 147,602.60 | -1.86 | 36.14 | -2.80 | 58.37 | 59.51 | 90.77 | -57.63 | 65.87 | 10.18 | -- | 0.0207 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| Taysha Gene Therapies Inc | 14.16m | -118.01m | 641.47m | 52.00 | -- | 11.91 | -- | 45.31 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 642.14m | 610.00 | -- | 1.59 | -- | 2.56 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 650.11m | 40.00 | -- | 2.05 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| AnaptysBio Inc | 22.96m | -163.30m | 654.01m | 117.00 | -- | 13.69 | -- | 28.48 | -6.13 | -6.13 | 0.862 | 1.75 | 0.048 | -- | 5.33 | 196,256.40 | -34.11 | -18.08 | -36.72 | -18.96 | -- | -- | -711.18 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 668.62m | 487.00 | -- | 0.9473 | -- | 7.34 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| National Research Corporation | 147.42m | 30.36m | 670.48m | 435.00 | 22.65 | 18.15 | 18.46 | 4.55 | 1.24 | 1.24 | 6.02 | 1.55 | 1.16 | -- | 11.53 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.55 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| SS Innovations International Inc | 11.22m | -22.75m | 684.66m | 239.00 | -- | 50.58 | -- | 61.03 | -0.1372 | -0.1372 | 0.0698 | 0.0793 | 0.6146 | -- | 2.43 | 46,943.05 | -124.63 | -161.38 | -289.30 | -449.76 | 11.08 | -79.79 | -202.80 | -495.77 | 0.8699 | -57.41 | 0.3901 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 706.18m | 224.00 | -- | 1.17 | -- | 10,385.02 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Regenxbio Inc | 86.73m | -260.15m | 706.82m | 344.00 | -- | 1.80 | -- | 8.15 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Phibro Animal Health Corp | 999.56m | 13.16m | 714.08m | 1.92k | 54.27 | 2.64 | 14.66 | 0.7144 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
Data as of Jun 03 2024. Currency figures normalised to National Research Corp's reporting currency: US Dollar USD
36.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Kayne Anderson Rudnick Investment Management LLCas of 31 Mar 2024 | 3.03m | 12.69% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 929.91k | 3.90% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 905.79k | 3.80% |
| Atlanta Capital Management Co. LLCas of 31 Mar 2024 | 885.53k | 3.71% |
| Conestoga Capital Advisors LLCas of 31 Mar 2024 | 784.66k | 3.29% |
| Dimensional Fund Advisors LPas of 31 Mar 2024 | 638.39k | 2.68% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 378.28k | 1.59% |
| Geode Capital Management LLCas of 31 Mar 2024 | 369.62k | 1.55% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 354.35k | 1.49% |
| Invesco Advisers, Inc.as of 31 Mar 2024 | 344.45k | 1.44% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
